Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood;
143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38048557
2.
An unusual form of BRAF-V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine.
Am J Hematol;
99(3): 497-501, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38264797
3.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol;
24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36528035
4.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica;
2023 Nov 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37981892
5.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol;
40(4): 704-715, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35608183
6.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol;
108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34716957
7.
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey.
Mycoses;
65(2): 171-177, 2022 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34695256
8.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol;
22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34774221
9.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica;
106(4): 1079-1085, 2021 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32107329
10.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Haematologica;
105(1): 193-200, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31221778
11.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica;
105(7): 1937-1947, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31582542
12.
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis.
Mycoses;
63(9): 900-910, 2020 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32531854
13.
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
J Antimicrob Chemother;
74(4): 1062-1068, 2019 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30649413
14.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.
Haematologica;
104(8): 1640-1647, 2019 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30733270
15.
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.
Haematologica;
108(1): 290-294, 2023 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35899391
16.
CAR T cell-driven cerebrospinal fluid cytokine storm with confounding neurological picture in chemorefractory primary cardiac lymphoma.
Am J Hematol;
98(1): 212-219, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36346356
17.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica;
106(1): 291-294, 2021 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32107338
18.
Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
J Antimicrob Chemother;
69(11): 3142-7, 2014 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24948702
19.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood;
120(1): 9-19, 2012 Jul 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22498745
20.
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey.
Int J Antimicrob Agents;
61(6): 106806, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37030470